Based on a modified version of the Brief Index of Sexual Functioning and Sexual History Form, tailored by endometriosis specialists to address endometriosis-specific issues, a survey was completed by 302 couples. To ascertain diverse viewpoints on shared sexuality within the partnership, the Wilcoxon test and Pearson chi-square test were employed.By assessing multiple facets of couple sexuality, both the man and woman attempted to identify differing viewpoints within their partnership.Regarding sexual satisfaction, preferred frequency, and the female partner's comfort levels during sexual activity, male and female partners frequently demonstrate contrasting perspectives. Their perspectives intersect on who takes the lead in sexual encounters, their pleasure with a variety of sexual activities, and how restrictions in their sexual interactions affect their satisfaction within the relationship.Endometriosis research demands acknowledgment of the roles and experiences of male partners, to fully address the complex interplay between sexuality and the condition. Likewise, women with endometriosis should be consulted within the framework of their relationships, not in isolation.This is the first analysis to utilize data from both partners in endometriosis-affected couples at such a comprehensive scale. Due to its exclusive focus on quantitative information, certain qualitative aspects have not been investigated.Given that both partners displayed a tendency to overestimate the other's sexual fulfillment and held contrasting perspectives on delicate sexual issues, such as the female partner's involvement in sexual activity despite discomfort, enhanced communication about sexuality could be a promising initial approach in couples counseling for endometriosis.Recognizing that both partners exhibited a pattern of overestimating their partner's sexual satisfaction, and had conflicting viewpoints on sensitive sexual topics, like the female partner's sexual activity despite discomfort, enhancing sexual communication could be a beneficial starting point in couples' counseling for endometriosis.The enhanced survival of lymphoma patients necessitates a heightened focus on long-term toxicity, the impact on overall quality of life, including sexual health.We set out to determine the prevalence of erectile dysfunction (ED) in adult male lymphoma survivors, investigating if there were associations with low testosterone, concurrent conditions, or lifestyle factors, and assessing their overall impact on quality of life.In a cross-sectional study, 172 male survivors of adult-onset Hodgkin lymphoma or diffuse large B-cell lymphoma, diagnosed between 2008 and 2018, were included. Initial treatment resulted in complete metabolic remission for patients, a remission that persisted during follow-up visits conducted three to thirteen years after their diagnosis. Participants undertook three questionnaires, focusing on sexual health and general well-being. Measurements of serum total testosterone levels were taken, along with detailed medical history and sociodemographic profiles. As reference values for the general population, the Danish SEXUS Project, the European Male Ageing Study, and the European Organization of Research and Treatment of Cancer (EORTC) Reference Manual were employed.Among the patient reported outcome measures, the 5-item International Index of Erectile Function, EORTC C30, and EORTC 22-item Sexual Health Questionnaire were included.ED reports increased by a substantial 552%, surpassing the 175% rate found in a matched Danish population group. The 5-item International Index of Erectile Function score (IIEF-5) displayed an inverse relationship with comorbidity, body mass index, smoking status, and age, and a positive relationship with the number of children conceived before treatment and serum total testosterone. Erectile dysfunction concurrent with overt testosterone deficiency was observed in 10 (57%) of 176 survivors, encompassing those who received hormonal treatment, a rate exceeding the prevalence in the general male population (1% to 32% for those under 70 years old). The mean EORTC C30 global health score for ED-affected survivors (677) fell below that of ED-free survivors (801), yet aligned with the general population's score of 712. Subsequently, there was a positive connection between sexual function and both sexual and overall quality of life scores.The impact of sexual health on quality of life is profound, and the relationship between it and related medical conditions is significant. Addressing both sexual health and comorbidities is essential for improving the quality of life in lymphoma patients during follow-up.Although the study encompassed a substantial number of survivors, the cross-sectional nature of the research necessitates longitudinal investigations to fully elucidate the root causes of sexual dysfunction.Among lymphoma survivors, ED was a common finding frequently accompanied by other health problems, signifying the importance of focusing more on sexual health and treatment-related comorbidities to improve both overall quality of life and sexual well-being.ED showed high prevalence in lymphoma survivors, often occurring alongside other health problems. Improving the quality of life for these individuals necessitates a heightened focus on sexual health and treatment-related comorbidities.A range of tools, including sexual stimuli such as sexual videos, images, and descriptions of sexual encounters, are utilized by clinicians and researchers to initiate or bolster sexual responses. In light of the extensive diversity within sexual stimuli and their consequences for sexual responses, we offer guidance on the appropriate use of sexual stimuli, the strategic selection of stimuli, and the standardization of their usage and reporting across research and clinical settings.This expert review of operating procedures details the use of sexual stimuli in clinical and research settings, encompassing three key areas: the settings where stimuli are employed, the characteristics and contexts of these stimuli, and the practical and ethical considerations surrounding their application.An expert evaluation of the sexual psychophysiology literature serves as the cornerstone of this article.We commence by investigating the settings in which sexual stimuli are commonly observed, subsequently evaluating the ecological validity for each case. Following this, we review the categories of sexual stimuli utilized in sexual response research, including physical characteristics, depictions of sexual behavior, and the surrounding context, and evaluate their impact on the resultant sexual response. Last but not least, we evaluate the practical and ethical aspects surrounding the application of sexual stimuli in both clinical and research environments. We analyze the potential restrictions imposed by certain sexual stimuli, including practical considerations like participant-experimenter agreements, and ethical concerns regarding representation and sourcing of stimuli, pertinent to clinical and research contexts. The use of virtual reality and other forms of sexual stimuli, as well as the ethical considerations surrounding user-created internet sexual content, are also explored in these discussions.Literature pertaining to the clinical and research applications of sexual stimuli is reviewed by experts, highlighting best practices and offering beneficial recommendations.Our review of the literature offers expert opinions on the application of sexual stimuli in clinical and research contexts, along with practical recommendations for optimal use.Live biotherapeutic fecal microbiota, designated as live-jslm (RBL; REBYOTA), has been granted the first FDA approval for microbiota-based treatment of recurrent conditions.Infection (rCDI) in adults has been scrutinized via five prospective clinical trials. Analyzing RBL's safety and effectiveness in patients with rCDI under varying FDA-approved conditions, mimicking actual treatment practices, with broad eligibility criteria.Between November 1, 2015, and September 30, 2019, five study sites retrospectively identified adults with rCDI who received RBL treatment under enforcement discretion. The CDI diagnosis was shaped by the site's particular method of practice. Patients who were not previously treated with RBL treatment, and possessed complete medical records for six months post-treatment, constituted the primary safety set (PSS).Among the primary treatment patients, 94 individuals were included; the PSS consisted of 64 patients with common comorbidities who were receiving various chronic treatments. dub inhibitors Mild to moderate treatment-emergent adverse events were similar in severity among comorbidity subgroups and the overall patient group. Related to RBL and the administration protocol, there were no critical adverse consequences recorded. Within the PSS, 828% of patients receiving RBL treatment displayed a response by the eighth week, and an impressive 887% of them maintained this response for the subsequent six months. Despite the number of RBL doses given, there was no discernible effect on the outcome.These findings, alongside projected clinical trial outcomes, support the efficacy and safety of RBL in preventing rCDI, representing real-world clinical practice through the inclusion of diagnostics and comorbidities.These findings, in conjunction with forthcoming clinical trial results, underscore the efficacy and safety of RBL in preventing rCDI, while diagnostics and comorbidities accurately represent real-world clinical practice.The rising trend of business-nonprofit partnerships stems from a desire to boost community benefits. Good intentions notwithstanding, discrepancies between the operational models of nonprofit and business organizations may obstruct the capacity for effective partnerships in reacting to evolving economic and public health realities.